Peel Hunt Reiterates “Add” Rating for Abcam (LON:ABC)

Share on StockTwits

Peel Hunt reiterated their add rating on shares of Abcam (LON:ABC) in a report published on Thursday morning, ThisIsMoney.Co.Uk reports.

A number of other equities analysts have also commented on the company. Liberum Capital reaffirmed a hold rating and issued a GBX 1,230 ($16.07) price objective on shares of Abcam in a research note on Monday, November 11th. JPMorgan Chase & Co. decreased their target price on shares of Abcam from GBX 1,144 ($14.95) to GBX 1,134 ($14.82) and set a neutral rating for the company in a research report on Monday, September 16th. Royal Bank of Canada restated a sector performer rating and set a GBX 1,300 ($16.99) price target on shares of Abcam in a report on Tuesday, November 12th. Finally, Berenberg Bank restated a buy rating and set a GBX 1,330 ($17.38) price target on shares of Abcam in a report on Monday, September 9th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of GBX 1,272.33 ($16.63).

Shares of ABC stock opened at GBX 1,374 ($17.95) on Thursday. Abcam has a 1-year low of GBX 1,006 ($13.15) and a 1-year high of GBX 1,523 ($19.90). The stock has a market cap of $2.83 billion and a price-to-earnings ratio of 63.03. The stock has a 50-day moving average of GBX 1,242.92 and a 200-day moving average of GBX 1,280.92.

In related news, insider Alan Thomas Hirzel sold 25,381 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of GBX 1,171 ($15.30), for a total transaction of £297,211.51 ($388,359.48). Also, insider Gavin Wood bought 2,500 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were acquired at an average cost of GBX 1,157 ($15.12) per share, with a total value of £28,925 ($37,795.64). In the last 90 days, insiders sold 199,884 shares of company stock worth $229,858,080.

Abcam Company Profile

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Further Reading: What is a recession?

Analyst Recommendations for Abcam (LON:ABC)

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

DORCHESTER WEALTH MANAGEMENT Co Lowers Stake in Verizon Communications Inc.
DORCHESTER WEALTH MANAGEMENT Co Lowers Stake in Verizon Communications Inc.
BLB&B Advisors LLC Has $10.25 Million Holdings in Exxon Mobil Co.
BLB&B Advisors LLC Has $10.25 Million Holdings in Exxon Mobil Co.
BLB&B Advisors LLC Sells 1,070 Shares of SPDR S&P 500 ETF Trust
BLB&B Advisors LLC Sells 1,070 Shares of SPDR S&P 500 ETF Trust
Procter & Gamble Co  Shares Purchased by DORCHESTER WEALTH MANAGEMENT Co
Procter & Gamble Co Shares Purchased by DORCHESTER WEALTH MANAGEMENT Co
Verizon Communications Inc.  Shares Purchased by Candriam Luxembourg S.C.A.
Verizon Communications Inc. Shares Purchased by Candriam Luxembourg S.C.A.
DORCHESTER WEALTH MANAGEMENT Co Acquires 440 Shares of Pfizer Inc.
DORCHESTER WEALTH MANAGEMENT Co Acquires 440 Shares of Pfizer Inc.


© 2006-2020 Ticker Report